Feasibility of MR Metabolomics for Immediate Analysis of Resection Margins during Breast Cancer Surgery

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Bathen, Tone F ^a,b   Geurts, Brigitte ^c   Sitter, Beathe ^d   Fjøsne, Hans E ^b   Lundgren, Steinar ^a,b   Buydens, Lutgarde M ^c   Gribbestad, Ingrid S ^a,b   Postma, Geert ^c   Giskeødegård, Guro F ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; GLUCOSE; GLYCINE; PHOSPHORYLCHOLINE; TAURINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; HIGH RESOLUTION MAGIC ANGLE SPINNING MAGNETIC RESONANCE SPECTROSCOPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; REOPERATION; SENSITIVITY AND SPECIFICITY; SURGEON; TISSUE SECTION; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; CHOLINE; DISCRIMINANT ANALYSIS; FEASIBILITY STUDIES; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS;

EID: 84876259314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061578     Document Type: Article

References (43)

1. Mistry M, Parkin DM, Ahmad AS, Sasieni P, (2011) Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 105: 1795-1803.
2. (2011) Cancer in Norway 2009- Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway.
3. Atkins J, Al Mushawah F, Appleton CM, Cyr AE, Gillanders WE, et al. (2012) Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors. J Surg Res 177: 109-115.
4. Lovrics PJ, Cornacchi SD, Farrokhyar F, Garnett A, Chen V, et al. (2009) The relationship between surgical factors and margin status after breast-conservation surgery for early stage breast cancer. Am J Surg 197: 740-746.
5. Fiehn O, (2002) Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 48: 155-171.
6. Sitter B, Bathen T, Tessem M, Gribbestad I, (2009) High-resolution magic angle spinning (HR MAS) MR spectroscopy in metabolic characterization of human cancer. Prog Nucl Magn Reson Spectrosc 54: 239-254.
7. Bathen TF, Sitter B, Sjøbakk TE, Tessem M-B, Gribbestad IS, (2010) Magnetic Resonance Metabolomics of Intact Tissue: A Biotechnological Tool in Cancer Diagnostics and Treatment Evaluation. Cancer Res 70: 6692-6696.
8. Giskeødegård GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, et al. (2010) Multivariate Modeling and Prediction of Breast Cancer Prognostic Factors Using MR Metabolomics. J Proteome Res 9: 972-979.
9. Lyng H, Sitter B, Bathen TF, Jensen LR, Sundfor K, et al. (2007) Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas. BMC Cancer 7: 11.
10. Martínez-Bisbal MC, Monleon D, Assemat O, Piotto M, Piquer J, et al. (2009) Determination of metabolite concentrations in human brain tumour biopsy samples using HR-MAS and ERETIC measurements. NMR Biomed 22: 199-206.
11. Seierstad T, Roe K, Sitter B, Halgunset J, Flatmark K, et al. (2008) Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy. Mol Cancer 7: 33.
12. Sitter B, Autti T, Tyynela J, Sonnewald U, Bathen TF, et al. (2004) High-resolution magic angle spinning and 1H magnetic resonance spectroscopy reveal significantly altered neuronal metabolite profiles in CLN1 but not in CLN3. J Neurosci Res 77: 762-769.
13. Sitter B, Bathen TF, Singstad TE, Fjøsne HE, Lundgren S, et al. (2010) Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed 23: 424-431.
14. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, et al. (2006) Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 19: 30-40.
15. Tessem M-B, Selnæs KM, Sjursen W, Tranø G, Giskeødegård GF, et al. (2010) Discrimination of patients with microsatelitte instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res 9: 3664-3670.
16. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, et al. (2008) Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 60: 510-516.
17. Yakoub D, Keun HC, Goldin R, Hanna GB, (2010) Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 70: 9129-9136.
18. Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS, (2002) High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 15: 327-337.
19. Piotto M, Moussallieh FM, Neuville A, Bellocq JP, Elbayed K, et al. (2012) Towards real-time metabolic profiling of a biopsy specimen during a surgical operation by 1H high resolution magic angle spinning nuclear magnetic resonance: a case report. J Med Case Rep 6: 22.
20. Sitter B, Bathen T, Hagen B, Arentz C, Skjeldestad FE, et al. (2004) Cervical cancer tissue characterized by high-resolution magic angle spinning MR spectroscopy. Magn reson Mater Phy 16: 174-181.
21. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, et al. (2006) Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 55: 1257-1264.
22. Li M, Song Y, Cho N, Chang JM, Koo HR, et al. (2011) An HR-MAS MR Metabolomics Study on Breast Tissues Obtained with Core Needle Biopsy. PLoS ONE 6: e25563.
23. Bloom HJ, Richardson WW, (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377.
24. Eilers PHC, (2004) Parametric Time Warping. Analytical Chemistry 76: 404-411.
25. Savorani F, Tomasi G, Engelsen SB, (2010) icoshift: A versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 202: 190-202.
26. Giskeødegård GF, Bloemberg TG, Postma G, Sitter B, Tessem M-B, et al. (2010) Alignment of high resolution magic angle spinning magnetic resonance spectra using warping methods. Anal Chim Acta 683: 1-11.
27. Massart DL, Vandeginste BGM, Buydens LMC, De Jong S, Lewi PJ, et al. (1997) Handbook of Chemometrics and Qualimetrics: Part B, Series: Data Handling in Science and Technology; Vandeginste BGM, Rutan SC, editors. Amsterdam: Elsevier.
28. Wold S, Sjöström M, Eriksson L, (2001) PLS-regression: a basic tool of chemometrics. Chem Intel Lab Syst 58: 109-130.
29. Keun HC, Ebbels TMD, Antti H, Bollard ME, Beckonert O, et al. (2003) Improved analysis of multivariate data by variable stability scaling: application to NMR-based metabolic profiling. Anal Chim Acta 490: 265-276.
30. Westerhuis J, Hoefsloot H, Smit S, Vis D, Smilde A, et al. (2008) Assessment of PLSDA cross validation. Metabolomics 4: 81-89.
31. Chong I-G, Jun C-H, (2005) Performance of some variable selection methods when multicollinearity is present. Chem Intel Lab Syst 78: 103-112.
32. Good PI (2000) Permutation tests: a practical guide to resampling methods for testing hypotheses: Springer New York.
33. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
34. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324: 1029-1033.
35. Glunde K, Bhujwalla ZM, Ronen SM, (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848.
36. Ackerstaff E, Glunde K, Bhujwalla ZM, (2003) Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90: 525-533.
37. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, et al. (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43: 869-874.
38. Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, et al. (2007) MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat 104: 181-189.
39. Giskeødegård GF, Lundgren S, Sitter B, Fjosne HE, Postma G, et al. (2012) Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed 25: 1271-1279.
40. Cao MD, Giskeodegard GF, Bathen TF, Sitter B, Bofin A, et al. (2012) Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 12: 39.
41. Borgan E, Lindholm EM, Moestue S, Maelandsmo GM, Lingjaerde OC, et al. (2012) Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts. Mol Oncol. pii: S1574-7891(12)00103-2. doi:10.1016/j.molonc.2012.10.005.
42. Moestue SA, Borgan E, Huuse EM, Lindholm EM, Sitter B, et al. (2010) Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 10: 433.
43. Wu C-L, Taylor JL, He W, Zepeda AG, Halpern EF, et al. (2003) Proton high-resolution magic angle spinning NMR analysis of fresh and previously frozen tissue of human prostate. Magn Reson Med 50: 1307-1311.